HRP20210902T1 - Postupci pojačavanja tonične inhibicije i liječenja angelmanovog sindroma - Google Patents
Postupci pojačavanja tonične inhibicije i liječenja angelmanovog sindroma Download PDFInfo
- Publication number
- HRP20210902T1 HRP20210902T1 HRP20210902TT HRP20210902T HRP20210902T1 HR P20210902 T1 HRP20210902 T1 HR P20210902T1 HR P20210902T T HRP20210902T T HR P20210902TT HR P20210902 T HRP20210902 T HR P20210902T HR P20210902 T1 HRP20210902 T1 HR P20210902T1
- Authority
- HR
- Croatia
- Prior art keywords
- composition
- use according
- pharmaceutically acceptable
- pharmaceutical composition
- thip
- Prior art date
Links
- 208000009575 Angelman syndrome Diseases 0.000 title claims 2
- 230000009478 tonic inhibition Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 claims 12
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- ZXRVKCBLGJOCEE-UHFFFAOYSA-N Gaboxadol Chemical compound C1NCCC2=C1ONC2=O ZXRVKCBLGJOCEE-UHFFFAOYSA-N 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- ZDZDSZQYRBZPNN-UHFFFAOYSA-N 4,5,6,7-tetrahydro-[1,2]oxazolo[5,4-c]pyridin-6-ium-3-olate;hydrochloride Chemical compound Cl.C1NCCC2=C1ONC2=O ZDZDSZQYRBZPNN-UHFFFAOYSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Steroid Compounds (AREA)
Claims (12)
1. Farmaceutska kompozicija koja sadrži efektivnu količinu 4,5,6,7-tetrahidroizoksazolo(5,4-c)piridin-3-ola (THIP) ili njegove farmaceutske efektivne soli i farmaceutski prihvatljiv nosač ili ekscipijens, za uporabu u postupku liječenja humanog subjekta sa Angelmanovim sindromom, pri čemu je efektivna količina 10 mg do 20 mg.
2. Kompozicija za uporabu prema zahtjevu 1, naznačena time da je THIP ili njegova farmaceutski prihvatljiva sol jedini aktivni sastojak.
3. Kompozicija za uporabu prema zahtjevu 2, naznačena time da se farmaceutska kompozicija sastoji od efektivne količine THIP ili njegove farmaceutski prihvatljive soli i jednog ili više farmaceutski prihvatljivih nosača ili ekscipijenasa.
4. Kompozicija za uporabu prema bilo kojem prethodnom zahtjevu, naznačena time da je farmaceutska kompozicija formulirana za produženo oslobađanje.
5. Kompozicija za uporabu prema bilo kojem prethodnom zahtjevu, naznačena time da se farmaceutska kompozicija administrira jednom na svakih 24-48 sati.
6. Kompozicija za uporabu prema bilo kojem prethodnom zahtjevu, naznačena time da se farmaceutska kompozicija administrira transdermalno.
7. Kompozicija za uporabu prema zahtjevu 6, naznačena time da se farmaceutska kompozicija administrira dovođenjem transdermalnog flastera koji sadrži farmaceutsku kompoziciju u kontakt s kožom subjekta.
8. Kompozicija za uporabu prema bio kojem prethodnom zahtjevu, naznačena time da se farmaceutska kompozicija administrira ujutro ili uvečer.
9. Kompozicija za uporabu prema bilo kojem prethodnom zahtjevu, naznačena time što, dnevna doza THIP ili njegove farmaceutski prihvatljive soli je između 10 mg i 20 mg.
10. Kompozicija za uporabu prema bilo kojem prethodnom zahtjevu, naznačena time što se kompozicija administrira na subjekta intravenski.
11. Kompozicija za uporabu prema bilo kojem prethodnom zahtjevu, naznačena time što se na subjekta administrira 15 mg THIP ili njegove farmaceutski prihvatljive soli.
12. Kompozicija za uporabu prema bilo kojem prethodnom zahtjevu, naznačena time što se THIP ili njegova farmaceutski prihvatljiva sol administrira jednom na dan.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462008939P | 2014-06-06 | 2014-06-06 | |
| EP18169211.2A EP3372229B1 (en) | 2014-06-06 | 2015-06-03 | Methods of increasing tonic inhibition and treating angelman syndrome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20210902T1 true HRP20210902T1 (hr) | 2021-09-17 |
Family
ID=54767324
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20210901TT HRP20210901T1 (hr) | 2014-06-06 | 2021-06-07 | Postupci pojačavanja tonične inhibicije i liječenja sekundarne nesanice |
| HRP20210902TT HRP20210902T1 (hr) | 2014-06-06 | 2021-06-07 | Postupci pojačavanja tonične inhibicije i liječenja angelmanovog sindroma |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20210901TT HRP20210901T1 (hr) | 2014-06-06 | 2021-06-07 | Postupci pojačavanja tonične inhibicije i liječenja sekundarne nesanice |
Country Status (19)
| Country | Link |
|---|---|
| US (10) | US20150352085A1 (hr) |
| EP (3) | EP3151832B1 (hr) |
| JP (4) | JP2017516868A (hr) |
| AR (1) | AR100772A1 (hr) |
| AU (4) | AU2015269667B2 (hr) |
| CA (1) | CA2950845C (hr) |
| CY (2) | CY1124366T1 (hr) |
| DK (2) | DK3372229T3 (hr) |
| ES (2) | ES2875742T3 (hr) |
| HR (2) | HRP20210901T1 (hr) |
| HU (2) | HUE055155T2 (hr) |
| IL (2) | IL249287B (hr) |
| LT (2) | LT3372229T (hr) |
| MX (2) | MX2020012404A (hr) |
| PL (2) | PL3151832T3 (hr) |
| PT (2) | PT3372229T (hr) |
| RS (2) | RS62007B1 (hr) |
| SI (2) | SI3151832T1 (hr) |
| WO (1) | WO2015187851A1 (hr) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3151832B1 (en) | 2014-06-06 | 2021-03-24 | Ovid Therapeutics, Inc. | Methods of increasing tonic inhibition and treating secondary insomnia |
| US10434308B2 (en) | 2015-05-29 | 2019-10-08 | Medtronic, Inc. | Impedance matching and electrode conditioning in patient interface systems |
| US10080898B2 (en) | 2015-05-29 | 2018-09-25 | Medtronic, Inc. | Simultaneous physiological sensing and stimulation with saturation detection |
| CA2992734A1 (en) * | 2015-07-17 | 2017-01-26 | Ovid Therapeutics, Inc. | Methods of treating developmental disorders with gaboxadol |
| US9682069B2 (en) | 2015-07-17 | 2017-06-20 | Ovid Therapeutics Inc | Methods of treating Dravet syndrome |
| WO2018017639A1 (en) * | 2016-07-19 | 2018-01-25 | Georgia State University Research Foundation | Methods for treating rett syndrome |
| BR112019002538A2 (pt) | 2016-08-11 | 2019-05-21 | Ovid Therapeutics Inc. | uso de uma composição farmacêutica compreendendo um modulador alostérico, uso de uma composição farmacêutica compreendendo garboxadol ou um sal farmaceuticamente aceitável do mesmo, e composição farmacêutica para a administração parenteral |
| AU2017363598A1 (en) * | 2016-11-22 | 2019-05-23 | Ovid Therapeutics Inc. | Methods of treating developmental disorders and/or seizure disorders with flupirtine |
| US10071083B2 (en) * | 2017-02-03 | 2018-09-11 | Ovid Therapeutics Inc | Use of gaboxadol in the treatment of tinnitus |
| US20180338959A1 (en) * | 2017-05-24 | 2018-11-29 | Ovid Therapeutics Inc. | Treatment of depressive disorders |
| WO2019028234A1 (en) | 2017-08-04 | 2019-02-07 | Ovid Therapeutics Inc. | USE OF GABOXADOL IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS |
| US11181384B2 (en) * | 2018-07-23 | 2021-11-23 | Waymo Llc | Verifying map data using challenge questions |
| EP3833351A4 (en) | 2018-09-20 | 2021-10-13 | Ovid Therapeutics Inc. | USE OF GABOXADOL TO TREAT TOURETTE SYNDROME, TICKS, AND STUTTERS |
| CA3120856A1 (en) * | 2018-11-21 | 2020-05-28 | Certego Therapeutics, Inc. | Gaboxadol for reducing risk of suicide and rapid relief of depression |
| CA3123876A1 (en) | 2018-12-17 | 2020-06-25 | Ovid Therapeutics Inc. | Use of gaboxadol for the treatment of non-24 hour sleep-wake disorder |
| US11786694B2 (en) | 2019-05-24 | 2023-10-17 | NeuroLight, Inc. | Device, method, and app for facilitating sleep |
| US20210015760A1 (en) * | 2019-07-15 | 2021-01-21 | Ovid Therapeutics Inc. | Pharmaceutical formulations containing gaboxadol for therapeutic treatment |
| EP4051272A4 (en) | 2019-12-18 | 2023-01-04 | Ovid Therapeutics Inc. | GABOXADOL FOR THE THERAPEUTIC TREATMENT OF 1p36 DELETION SYNDROME |
| JP2023526439A (ja) | 2020-05-20 | 2023-06-21 | セルテゴ セラピューティクス インコーポレイテッド | 精神障害の処置のための環重水素化ガボキサドールおよびその使用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK270378A (da) | 1977-06-20 | 1978-12-21 | Krogsgaard Larsen P | Isoxazolderivater |
| US4362731A (en) | 1980-09-01 | 1982-12-07 | Sandoz Ltd. | Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof |
| US4353910A (en) | 1981-11-27 | 1982-10-12 | Kefalas A/S | Derivatives of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridine-3-one, pharmaceutical compositions and methods of treatment |
| DE19525598C2 (de) | 1995-07-13 | 1997-09-25 | Max Planck Gesellschaft | Schlafmittel |
| DE19526864A1 (de) | 1995-07-22 | 1997-01-23 | Labtec Gmbh | Hormonpflaster |
| US6461644B1 (en) | 1996-03-25 | 2002-10-08 | Richard R. Jackson | Anesthetizing plastics, drug delivery plastics, and related medical products, systems and methods |
| US5948433A (en) | 1997-08-21 | 1999-09-07 | Bertek, Inc. | Transdermal patch |
| US6676961B1 (en) | 2002-03-06 | 2004-01-13 | Automated Carrier Technologies, Inc. | Transdermal patch assembly |
| US20050137222A1 (en) * | 2003-12-18 | 2005-06-23 | H. Lundbeck A/S | Treatment of insomnia in human patients |
| JP2007530604A (ja) | 2004-04-02 | 2007-11-01 | ハー・ルンドベック・アクチエゼルスカベット | 呼吸機能障害の治療 |
| DE102005020882A1 (de) * | 2005-05-04 | 2006-11-09 | Dömling, Alexander, Dr. | Verwendung von Gaboxadol und Derivaten zur Behandlung von Kinase-induzierten Krankheiten |
| US20110046090A1 (en) * | 2005-10-31 | 2011-02-24 | Braincells Inc. | Modulation of neurogenesis with gaba agents and gaba analogs |
| US20090143335A1 (en) | 2007-10-29 | 2009-06-04 | H. Lundbeck A/S | Modified absorption formulation of gaboxadol |
| CA2705733C (en) | 2007-11-13 | 2015-02-03 | Cadence Pharmaceuticals | Reduced dose intravenous acetaminophen |
| EP2334299A1 (en) * | 2008-09-01 | 2011-06-22 | H. Lundbeck A/S | Pharmaceutical composition comprising gaboxadol and an inhibitor of patl or oat |
| EP3151832B1 (en) | 2014-06-06 | 2021-03-24 | Ovid Therapeutics, Inc. | Methods of increasing tonic inhibition and treating secondary insomnia |
| CA2992734A1 (en) * | 2015-07-17 | 2017-01-26 | Ovid Therapeutics, Inc. | Methods of treating developmental disorders with gaboxadol |
| US9399034B1 (en) | 2015-08-11 | 2016-07-26 | Ovid Therapeutics Inc | Methods of sedation during critical care treatment |
-
2015
- 2015-06-03 EP EP15803364.7A patent/EP3151832B1/en active Active
- 2015-06-03 DK DK18169211.2T patent/DK3372229T3/da active
- 2015-06-03 ES ES18169211T patent/ES2875742T3/es active Active
- 2015-06-03 LT LTEP18169211.2T patent/LT3372229T/lt unknown
- 2015-06-03 SI SI201531616T patent/SI3151832T1/sl unknown
- 2015-06-03 ES ES15803364T patent/ES2876350T3/es active Active
- 2015-06-03 DK DK15803364.7T patent/DK3151832T3/da active
- 2015-06-03 PT PT181692112T patent/PT3372229T/pt unknown
- 2015-06-03 CA CA2950845A patent/CA2950845C/en active Active
- 2015-06-03 LT LTEP15803364.7T patent/LT3151832T/lt unknown
- 2015-06-03 MX MX2020012404A patent/MX2020012404A/es unknown
- 2015-06-03 PL PL15803364T patent/PL3151832T3/pl unknown
- 2015-06-03 PL PL18169211T patent/PL3372229T3/pl unknown
- 2015-06-03 EP EP18169211.2A patent/EP3372229B1/en active Active
- 2015-06-03 WO PCT/US2015/034018 patent/WO2015187851A1/en active Application Filing
- 2015-06-03 SI SI201531620T patent/SI3372229T1/sl unknown
- 2015-06-03 PT PT158033647T patent/PT3151832T/pt unknown
- 2015-06-03 US US14/729,910 patent/US20150352085A1/en not_active Abandoned
- 2015-06-03 AU AU2015269667A patent/AU2015269667B2/en active Active
- 2015-06-03 JP JP2017516256A patent/JP2017516868A/ja not_active Withdrawn
- 2015-06-03 EP EP20204995.3A patent/EP3795156A1/en active Pending
- 2015-06-03 RS RS20210718A patent/RS62007B1/sr unknown
- 2015-06-03 HU HUE15803364A patent/HUE055155T2/hu unknown
- 2015-06-03 MX MX2016016136A patent/MX2016016136A/es unknown
- 2015-06-03 RS RS20210711A patent/RS62006B1/sr unknown
- 2015-06-03 HU HUE18169211A patent/HUE055400T2/hu unknown
- 2015-06-05 AR ARP150101808A patent/AR100772A1/es not_active Application Discontinuation
- 2015-10-19 US US14/886,764 patent/US9339495B2/en active Active
-
2016
- 2016-04-19 US US15/132,641 patent/US9446028B2/en active Active
- 2016-11-04 US US15/343,690 patent/US9744159B2/en active Active
- 2016-11-29 IL IL249287A patent/IL249287B/en active IP Right Grant
- 2016-12-12 US US15/375,735 patent/US9801864B2/en active Active
-
2017
- 2017-06-09 US US15/618,736 patent/US20170273956A1/en not_active Abandoned
- 2017-09-27 US US15/716,726 patent/US20180015076A1/en not_active Abandoned
-
2018
- 2018-06-29 US US16/023,282 patent/US11278529B2/en active Active
-
2019
- 2019-08-27 IL IL268960A patent/IL268960B/en active IP Right Grant
- 2019-11-29 JP JP2019217208A patent/JP2020063264A/ja not_active Withdrawn
-
2020
- 2020-08-11 AU AU2020217342A patent/AU2020217342B2/en active Active
-
2021
- 2021-06-07 HR HRP20210901TT patent/HRP20210901T1/hr unknown
- 2021-06-07 HR HRP20210902TT patent/HRP20210902T1/hr unknown
- 2021-06-10 CY CY20211100509T patent/CY1124366T1/el unknown
- 2021-06-10 CY CY20211100510T patent/CY1124368T1/el unknown
- 2021-07-15 JP JP2021116935A patent/JP2021178836A/ja active Pending
- 2021-09-30 US US17/490,650 patent/US20220016091A1/en not_active Abandoned
-
2022
- 2022-01-07 AU AU2022200085A patent/AU2022200085A1/en not_active Abandoned
- 2022-08-08 US US17/882,939 patent/US20230051859A1/en active Pending
-
2023
- 2023-05-30 JP JP2023088456A patent/JP2023123442A/ja active Pending
-
2024
- 2024-04-22 AU AU2024202604A patent/AU2024202604A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210902T1 (hr) | Postupci pojačavanja tonične inhibicije i liječenja angelmanovog sindroma | |
| NI201900099A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| ECSP18073366A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| BR112015029491A2 (pt) | derivados de imidazopirrolidinona e seu uso no tratamento de doença | |
| MX2021013139A (es) | Composicion farmaceutica para la prevencion y/o tratamiento de dermatitis atopica que comprende antagonista de interleucina 31 (il-31) como ingrediente activo. | |
| EA201391315A1 (ru) | Гуанидиновое соединение | |
| ECSP19083640A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| MY180145A (en) | Cenicriviroc compositions and methods of making and using the same | |
| RU2018135973A (ru) | Фармацевтическая комбинация, содержащая метроформин и дигидрокверценин, и ее применение для лечения рака | |
| BR112015029401A8 (pt) | derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas | |
| AR097619A1 (es) | Uso de inhibidores de acetil-coa carboxilasa para tratar acné vulgaris | |
| FI3666258T3 (fi) | Menetelmä prader-willin oireyhtymän hoitamiseksi | |
| RU2018125622A (ru) | Способ применения карримицина против резистетности инфекции, спровоцированной микобактерией туберкулеза | |
| EA201270651A1 (ru) | Карбоксамиды пиридинон гидроксициклопентила: ингибиторы вич интегразы и области терапевтического применения | |
| PH12019502376A1 (en) | Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication | |
| HRP20240309T1 (hr) | Kombinirani antibakterijski pripravak i kratkotrajni antibakterijski režim, koji uključuje linezolid, bedakvilin i pretomanid | |
| UY34896A (es) | Tratamiento de la esclerosis múltiple con una combinación de laquinimod y fampridina | |
| BR112019007863A2 (pt) | derivados de naftiridinona inovadores e seu uso no tratamento de arritmia | |
| HRP20230300T1 (hr) | Kombinacije imetelstata i venetoklaksa za liječenje akutne mijeloidne leukemije | |
| MX2014014814A (es) | Composicion farmaceutica para el tratamiento de inflamacion y dolor. | |
| ECSP16005208A (es) | Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido recubierto que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación | |
| SG10201803996WA (en) | Anti-tuberculosis stable pharmaceutical composition in a form of a dispersible tablet comprising granules of isoniazid and granules of rifapentine and its process of preparation | |
| AR108792A1 (es) | Composiciones que comprenden timolol | |
| MX2018013474A (es) | Acidos carboxilicos para aplicacion en la primera infancia. | |
| EA201592261A1 (ru) | Фармацевтические композиции, включающие агомелатин в форме сокристаллов агомелатина с органической кислотой |